How does Cyramza treat gastric cancer?

What are the key benefits of Cyramza in treating gastric cancer?

Cyramza, also known as ramucirumab, is a monoclonal antibody that treats gastric cancer by inhibiting angiogenesis, or the formation of new blood vessels, which feeds tumor growth. [1] According to the drug's manufacturer, Eli Lilly, [2] the FDA approved Cyramza in 2014 for use in combination with paclitaxel to treat patients with advanced or metastatic gastric cancer.

How does Cyramza compare to other cancer treatments?

Cyramza has been shown to improve overall survival and progression-free survival in patients with advanced gastric cancer compared to chemotherapy alone. [3] In a clinical trial, Cyramza and paclitaxel resulted in a median overall survival of 5.72 months, compared to 3.75 months with chemotherapy alone. [4]

What are the potential side effects of Cyramza?

Common side effects of Cyramza include fatigue, anemia, headache, and peripheral edema. [5] More severe side effects can include pulmonary embolism, deep vein thrombosis, and hypertension. Patients should be closely monitored for these potential complications during treatment.

When can patients expect to see the benefits of Cyramza?

The effects of Cyramza can be seen as early as two weeks after treatment initiation. Patients may experience improved symptoms, such as reduced fatigue and weight loss, and stabilization of tumor growth. However, it may take months for the full benefits of treatment to develop.

Who is eligible for Cyramza treatment?

Patients with advanced or metastatic gastric cancer, including those whose cancer has progressed after first-line treatment, may be eligible for Cyramza. Those with a history of severe allergic reactions, bleeding disorders, or certain types of cancer may not be candidates for this treatment.

When does the patent for Cyramza expire?

The patent for Cyramza expired in [2023] [6]. Generic versions of the drug may enter the market once the patent expires.

Sources:
[1] https://www.druggabletargetcentral.ca/drug/DT000656
[2] https://www.lilly.com/about-us/media-room/press-releases/2014/4-15-2014-ramucirumab-receives-fda-approval-for-treatment-of-advanced-gastric-cancer
[3] https://www.nejm.org/doi/10.1056/NEJMoa1411482
[4] Eli Lilly and Company.
[5] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125528Orig1s000lb.pdf
[6] DrugPatentWatch.com